According to a , treatment with pembrolizumab and neoadjuvant chemotherapy resulted in higher pathological complete response rates than did treatment with placebo and neoadjuvant chemotherapy in patients with previously untreated, stage II or III triple-negative breast cancer.

中文翻译：

---

派姆单抗用于三阴性乳腺癌。

根据a，在先前未治疗的II或III期三阴性乳腺癌患者中，与接受安慰剂和新辅助化疗相比，使用pembrolizumab和新辅助化疗进行治疗的病理学完全缓解率更高。